XML 131 R10.htm IDEA: XBRL DOCUMENT v3.24.2.u1

Accrued expenses

6 Months Ended

Jun. 30, 2024

Payables and Accruals [Abstract]

Accrued expenses

Accrued expenses

Accrued expenses consisted of the following (in thousands):

						June 30,						December 31,
						2024						2023
Clinical trial and other development costs						$	5,959					$	752
Professional fees and general corporate costs						5,095						2,039
People related costs						3,964						794
Debt issuance costs						4,612						—
Total accrued expenses						$	19,630					$	3,585

X

- Definition

The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a),20,24)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

+ Details

Name:	us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_PayablesAndAccrualsAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration